Cessatech reports successful outcome of pharmacokinetic trial in children of lead candidate
· Clinical trial 0206 investigated the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures. · Primary endpoint was successfully met by obtaining pharmacokinetic data in this age group, showing relevant clinical exposure ranges. · Secondary objectives of safety, pain assessment, and acceptance of intranasal administration was at an acceptable levelCessatech A/S announces positive topline outcome of its Phase 1 pharmacokinetics trial with CT001 in children, which met the primary endpoint of the trial. The trial was designed as a non-randomised, open-